glp-1amide

GLP-1 secretion by human enteroendocrine NCI-H716 cells is augmented in a dose-dependent manner by the addition of CPE.

GLP-1(32-36)amide acetate is a pentapeptide and derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide acetate could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.

GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is an important compound that functions as an antioxidant primarily targeting the mitochondrion to inhibit mitochondrial permeability transition (MPT), displaying anti-diabetic properties and cardioprotection effects[1].

GLP-1(28-36)amide acetate inhibits mitochondrial permeability transition with antioxidant, anti-diabetic and cardioprotection activities.

GLP-1(32-36)amide is a pentapeptide compound derived from the C terminus of the glucoregulatory hormone GLP-1. This compound has shown potential in inhibiting weight gain and regulating glucose metabolism in diabetic mice[1][2].